Kroger has expanded its pharmacy offerings by adding Eli Lilly’s Zepbound® KwikPen, a multi‑dose delivery system for the weight‑management drug. The product is now available at participating Kroger pharmacies and can be purchased through Lilly’s KwikPen Self‑Pay Savings Card, which lowers out‑of‑pocket costs for eligible patients.
The launch follows Lilly’s late‑February 2026 direct‑to‑consumer rollout of the KwipPen and the FDA approval of the label expansion on January 20 2026. Kroger’s pharmacy associates will help patients navigate insurance benefits, manufacturer programs, and discount cards, positioning the chain as a convenient access point for high‑margin GLP‑1 therapies.
Kroger’s Q4 2025 earnings, released on March 5 2026, showed an adjusted EPS of $1.28, beating analyst expectations of $1.20 by $0.08. Revenue of $34.73 billion fell slightly short of the $35.00 billion forecast, a miss of $0.27 billion. The company cited a mix of strong e‑commerce growth and modest headwinds in its core grocery business as drivers of the revenue shortfall.
Management highlighted the pharmacy expansion as a key growth lever. CEO Greg Foran emphasized operational discipline and the importance of high‑margin pharmacy services, while Group Vice President Colleen Lindholz noted that the KwikPen “provides a convenient, cost‑effective option for self‑pay patients.” The move is intended to increase prescription volume and customer loyalty, reinforcing Kroger’s strategy to capture a larger share of the rapidly expanding GLP‑1 market.
Kroger’s FY2026 guidance remains unchanged, with adjusted EPS projected at $5.10–$5.30, reflecting confidence in continued earnings growth. The company’s focus on pharmacy services, e‑commerce, and alternative profit businesses underpins its outlook, while the new product launch is expected to contribute to the high‑margin segment’s expansion.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.